ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19
Launched by HOSPITAL UNIVERSITARI VALL D'HEBRON RESEARCH INSTITUTE · Feb 14, 2025
Trial Information
Current as of August 19, 2025
Completed
Keywords
ClinConnect Summary
The Registry on patients with rare red blood cell disorders (RBCDs) and COVID-19 is an initiative conceived in the core of the European Reference Network on Rare Hematological Diseases (ERN-EuroBloodNet, FPA 739541, www.eurobloodnet.eu) aiming at supporting medical practice of COVID-19 in these patients by gathering evidence on pediatric and adult COVID-19 confirmed cases in RBCDs across Europe.
Primary objective of the registry is to pool evidence on the clinical management and outcomes of patients affected by red blood cell disorders and COVID-19 for supporting daily medical practice whi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients both pediatric and adults with confirmed COVID-19 and affected by a rare anaemia disorder due to a red blood cell defect
About Hospital Universitari Vall D'hebron Research Institute
The Hospital Universitari Vall d'Hebron Research Institute (VHIR) is a leading biomedical research center affiliated with Vall d'Hebron University Hospital in Barcelona, Spain. Committed to advancing healthcare through innovative research, VHIR focuses on translating scientific discoveries into clinical applications, enhancing patient care and outcomes. The institute fosters collaboration among multidisciplinary teams of researchers, clinicians, and industry partners, emphasizing excellence in translational medicine, clinical trials, and public health initiatives. With a strong emphasis on ethical standards and patient safety, VHIR is dedicated to contributing to the global body of knowledge in various medical fields.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Barcelona, , Spain
Patients applied
Trial Officials
María del Mar Mañú Pereira, PhD
Principal Investigator
Vall d'Hebron Institut de Recerca, Barcelona (Spain) and ERN-EuroBloodNet
Pablo Velasco Puyó, MD
Principal Investigator
Vall d'Hebron University Hospital, Barcelona (Spain)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported